Related Experiment Video
Updated: Apr 22, 2026

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head
Published on: January 3, 2020
Intermittent everolimus administration for malignant insulinoma
Chiara Baratelli1, Maria Pia Brizzi1, Marco Tampellini1
1Dipartimento di Oncologia, Oncologia Medica, Università di Torino, Azienda Ospedaliero Universitaria San Luigi Gonzaga , Regione Gonzole 1010043, Orbassano , Italy.
Unlabelled:
Insulinoma is a rare form of insulin-secreting pancreatic islet cell neuroendocrine (NE) tumor. The medical treatment of the malignant NE disease of the pancreas deeply changed in the last years, thanks to the introduction of new target molecules, as everolimus. Even if the exact mechanism is not actually known, one of the side effects of everolimus, hyperglycemia, has been demonstrated to be useful to contrast the typical hypoglycemia of the insulinoma. We report the case of a patient with a metastatic malignant insulinoma treated with intermittent everolimus, obtaining an important improvement in the quality of life; this suggests the necessity of preclinical studies to analyze the cellular pathways involved in insulin-independent gluconeogenesis.
Learning Points:
Effect of somatostatin analogs is long-lasting in the control of functioning NE tumors.Persistent everolimus control of hypoglycemia despite serum insulin levels and disease progression.OPEN ISSUE: are disease progression and the increase in serum markers the only valid criteria to reject a treatment?
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Drug Dosing: Obese Patients

